Prognostic Value of Novel Biomarkers on Adverse Renal Outcomes in High-Risk Cardiac Surgery Patients

Last updated: February 23, 2026
Sponsor: Guowei Tu
Overall Status: Active - Recruiting

Phase

N/A

Condition

Kidney Failure

Kidney Disease

Renal Failure

Treatment

Standard care "bundle"

Clinical Study ID

NCT07418242
B2025-549
  • Ages 18-90
  • All Genders

Study Summary

This project aims to detect novel biomarkers from preoperative and early postoperative serum and urine samples of patients to screen and analyze the risk factors for predicting adverse postoperative renal outcomes in high-risk patients in cardiac surgery.

Eligibility Criteria

Inclusion

Adult patients were included in the study if they were scheduled for elective open chest cavity cardiac surgeries, with or without the use of cardiopulmonary bypass (CPB). Inclusion criteria required that patients undergoing surgery with CPB must have at least one AKI risk factor, whereas those undergoing surgery without CPB needed to have at least two AKI risk factors.

The AKI risk factors were as follows:

  • age >70 years;

  • 30 < estimated glomerular filtration rate (eGFR) <60 mL·min-1·1.73 m-2;

  • diabetes mellitus, proteinuria;

  • a history of congestive heart failure within the previous year;

  • a left ventricular ejection fraction of 40% or lower;

  • prior cardiac surgery;

  • combined coronary artery bypass/valve procedure;

  • urgent procedure;

  • preoperative intra-aortic balloon pump.

Exclusion

Exclusion criteria:

  • pre-existing chronic kidney disease (preoperative estimated glomerular filtrationrate [eGFR] < 30 mL/min/1.73 m2);

  • previous RRT before cardiac surgery;

  • present AKI at screening;

  • a history of kidney transplant or other kidney diseases;

  • known pregnancy;

  • multiple operation during the hospital stay;

  • being in a moribund state (with an anticipated likelihood of death within 48 hours).

Study Design

Total Participants: 1491
Treatment Group(s): 1
Primary Treatment: Standard care "bundle"
Phase:
Study Start date:
February 23, 2026
Estimated Completion Date:
May 31, 2029

Study Description

This project will prospectively collect all high-risk individuals who underwent cardiac surgery, collect medical history, laboratory data and specimen test results, and test biomarkers in blood and urine specimens. Previously identified candidate biomarkers include the tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR), galectin-9 (Gal-9), perilipin-2 (Plin2), and CCN family member 1, among others. The occurrence of postoperative AKI will be the primary endpoint of the study. The variable factors that can be used to predict and warn the main research endpoints at an early stage were screened through methods such as logistic regression, and their non-inferiority compared with traditional markers was tested. This study will facilitate early clinical identification and early warning of AKI, early implementation of preventive measures and intervention strategies, thereby improving the prognosis of patients and improve the overall safety and success rate of cardiac surgery.

Connect with a study center

  • Zhongshan hospital

    Shanghai 1796236, Shanghai Municipality 1796231 200032
    China

    Active - Recruiting

  • Zhongshan hospital, Fudan university

    Shanghai 1796236, Shanghai Municipality 1796231 200030
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.